E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
recurrent/metastatic head and neck squamous cell cancer |
|
E.1.1.1 | Medical condition in easily understood language |
cancer of the head & neck that has come back or spread to other parts of the body |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10067821 |
E.1.2 | Term | Head and neck cancer |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10060121 |
E.1.2 | Term | Squamous cell carcinoma of head and neck |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
This trial is divided into two parts; a safety run-in and the phase II part of the trial. The objective of the safety run in is to make sure the combination of cetuximab and avelumab at the doses we have selected for the study are safe and tolerable. In phase II, the main question we want to answer is whether or not giving avelumab and cetuximab together is better than giving avelumab alone to treat patients with head and neck cancer that have had previous treatment with cisplatin and whose cancer has come back or spread to other parts of the body. We will compare the number of patients in each group whose cancer has not gotten any worse 6 months after joining the study.
|
|
E.2.2 | Secondary objectives of the trial |
We will look at other measures of how effective the two treatments are, such as in how many patients does the cancer shrink, how long does it take before the cancer starts to grow, and how long do the patients live. We will also look at the side effects to see whether one treatment has more or less side effects than the other. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Histologically/cytologically confirmed recurrent/metastatic squamous cell carcinoma of the head and neck that is considered incurable by local therapies. (NB: for the safety run-in, this criterion is replaced by "Histologically or cytologically confirmed recurrent or metastatic squamous cell carcinoma that is considered incurable by local therapies.") 2. Prior treatment with a platinum agent (either for recurrent/metastatic disease; or as part of radical intent multi-modality treatment if disease has recurred within 6 months). (NB: This cirterion is not applicable for the safety run-in). 3. No previous treatment with cetuximab for metastatic/recurrent disease 4. Age ≥18 years 5. WHO Performance Status 0 or 1 6. Measurable disease according to RECIST v1.1 7. Adequate bone marrow function 8. Adequate liver function 9. Adequate renal function 10. Adequate venous access for administration of treatment and collection blood samples for exploratory biological samples 11. Willing to have a new biopsy (NB: This criterion is not applicable for the safety run-in). 12. Life expectancy of >3 months 13. Women of child-bearing potential and male patients with partners of child-bearing potential must agree to use adequate contraception methods from date of informed consent, which must be continued for 120 days after completion of trial treatment. 14. Able to give informed consent, indicating that the patient has been informed of and understands the experimental nature of the study, possible risks and benefits, trial procedures, and alternative options 15. Willing and able to comply with the protocol for the duration of the study, including the treatment plan, investigations required and follow up visits.
|
|
E.4 | Principal exclusion criteria |
1. Patients with undifferentiated nasopharyngeal or sino-nasal cancers. 2. Disease suitable for treatment with curative intent. 3. Prior therapy with an anti-PD-1, anti-PD-L1 or anti-PD-L2 agent. 4. Treatment with any investigational agent within 4 weeks prior to the first dose of trial treatment. 5. Anti-cancer monoclonal antibody therapy within 4 weeks prior to randomisation 6. Chemotherapy, targeted small molecule therapy, or radiotherapy within 2 weeks prior to randomisation. 7. Persisting grade ≥2 toxicity related to prior therapy 8. Patients with concurrent or previous malignancy that could compromise assessment of the primary or secondary endpoints of the trial. 9. Women who are pregnant or breast feeding. 10. Grade 3 or 4 peripheral neuropathy. 11. Any serious and/or unstable pre-existing medical, psychiatric or other condition, or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study. 12. Patients who are not able to give informed consent for any reason. 13. Active central nervous system (CNS) metastases and/or carcinomatous meningitis 14. Hepatitis infection at screening 15. Known history of testing positive for HIV or known acquired immunodeficiency syndrome. 16. Prior organ transplantation including allogenic stem-cell transplantation 17. Has a history of (non-infectious) pneumonitis that required steroids, or current pneumonitis 18. Active infection requiring systemic therapy 19. Has received a live vaccine within 28 days prior to first dose of trial treatment 20. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment (n.b. the use of physiologic doses of corticosteroids may be approved after consultation with UCL CTC) 21. Active autoimmune disease that might deteriorate when receiving an immune-stimulatory agent. 22. Current use of immunosuppressive medication 23. History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organising pneumonia (i.e. bronchiolitis obliterans, cryptogenic organising pneumonia), or evidence of active pneumonitis on screening chest CT scan. (History of radiation pneumonitis in the radiation field is permitted). 24. Significant cardiovascular disease 25. Known prior severe hypersensitivity to either investigational product or any component in their formulations, including known severe hypersensitivity reactions to monoclonal antibodies 26. Other severe acute or chronic medical conditions including immune colitis, inflammatory bowel disease, immune pneumonitis, pulmonary fibrosis. 27. Patients with a history of keratitis, ulcerative keratitis or severe dry eye.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Disease control rate (DCR) at 24 weeks after randomisation. Disease control is defined as the absence of objective progression according to iRECIST. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
24 weeks after randomisation |
|
E.5.2 | Secondary end point(s) |
1) Objective response (iCR or iPR) at 6 and 12 months using iRECIST 2) DC at 12 months using iRECIST 3) Duration of response using iRECIST 4) Best overall response (OR) using iRECIST 5) Time to progression (TTP) 6) Progression free survival (PFS) 7) Overall survival (OS) 8) Frequency and severity of adverse events 9) Treatment related dose delays or treatment discontinuation
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1) 6 and 12 months after randomisation 2) 12 months after randomisation 3) From first response assessment showing iCR or iPR to assessment documenting iPD 4) From start of treatment to end of follow up 5) Randomisation to date of first progression 6) Randomisation to date last known alive 7) Randomisation to death from any cause
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 12 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
For regulatory purposes the end of the trial will be 24 months after registration of the final patient, or once all patients have progressed or died, whichever is sooner. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 5 |
E.8.9.1 | In the Member State concerned days | 31 |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 5 |
E.8.9.2 | In all countries concerned by the trial days | 31 |